Use of administrative data to identify off-label use of second-generation antipsychotics in a medicaid population

Daniel M. Hartung, Luke Middleton, Bentson McFarland, Dean G. Haxby, Marian McDonagh, Kenneth (John) McConnell

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: The use of second-generation antipsychotics for conditions not approved by the U.S. Food and Drug Administration (FDA) is a prevalent phenomenon with important implications. The objective of this study was to determine the accuracy of administrative claims for identifying off-label use of second-generation antipsychotics in a Medicaid population in 2009. Methods: The authors estimated the sensitivity, specificity, positive predictive values (PPV), and negative predictive values of Medicaid claims data for detecting off-label use of second-generation antipsychotics in the electronic health records of 788 patients. Separate estimates were calculated for patients without schizophrenia and bipolar disorder, the two most long-standing FDA indications for use of second-generation antipsychotics, and for a subset of patients using a second-generation antipsychotic with indications for treatment-resistant depression. Results: Medicaid claims determined a lack of schizophrenia and bipolar disorder in the medical record with a sensitivity of 72% and a specificity of 85%. The prevalence of identifying neither diagnosis was 83%, which was associated with a predictive ability (PPV) of 96%. Among those using a second-generation antipsychotic with an indication for treatment-resistant depression, the sensitivity, specificity, and PPV of Medicaid claims for identifying off-label use were 41%, 86%, and 87%, respectively. Conclusions: Medicaid claims data had high predictive ability for identifying users of second-generation antipsychotics who did not have documentation of schizophrenia or bipolar disorder in the medical record. The predictive utility of the claims was diminished when the analyses were limited to patients using a second-generation antipsychotic with an indication for treatment-resistant depression.

Original languageEnglish (US)
Pages (from-to)1236-1242
Number of pages7
JournalPsychiatric Services
Volume64
Issue number12
DOIs
StatePublished - Dec 1 2013

Fingerprint

Off-Label Use
Medicaid
Antipsychotic Agents
Treatment-Resistant Depressive Disorder
Population
Bipolar Disorder
Schizophrenia
Aptitude
United States Food and Drug Administration
Medical Records
Sensitivity and Specificity
Electronic Health Records
Documentation

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Use of administrative data to identify off-label use of second-generation antipsychotics in a medicaid population. / Hartung, Daniel M.; Middleton, Luke; McFarland, Bentson; Haxby, Dean G.; McDonagh, Marian; McConnell, Kenneth (John).

In: Psychiatric Services, Vol. 64, No. 12, 01.12.2013, p. 1236-1242.

Research output: Contribution to journalArticle

Hartung, Daniel M. ; Middleton, Luke ; McFarland, Bentson ; Haxby, Dean G. ; McDonagh, Marian ; McConnell, Kenneth (John). / Use of administrative data to identify off-label use of second-generation antipsychotics in a medicaid population. In: Psychiatric Services. 2013 ; Vol. 64, No. 12. pp. 1236-1242.
@article{a7de9641e9e145d58a95e0fc028b8674,
title = "Use of administrative data to identify off-label use of second-generation antipsychotics in a medicaid population",
abstract = "Objective: The use of second-generation antipsychotics for conditions not approved by the U.S. Food and Drug Administration (FDA) is a prevalent phenomenon with important implications. The objective of this study was to determine the accuracy of administrative claims for identifying off-label use of second-generation antipsychotics in a Medicaid population in 2009. Methods: The authors estimated the sensitivity, specificity, positive predictive values (PPV), and negative predictive values of Medicaid claims data for detecting off-label use of second-generation antipsychotics in the electronic health records of 788 patients. Separate estimates were calculated for patients without schizophrenia and bipolar disorder, the two most long-standing FDA indications for use of second-generation antipsychotics, and for a subset of patients using a second-generation antipsychotic with indications for treatment-resistant depression. Results: Medicaid claims determined a lack of schizophrenia and bipolar disorder in the medical record with a sensitivity of 72{\%} and a specificity of 85{\%}. The prevalence of identifying neither diagnosis was 83{\%}, which was associated with a predictive ability (PPV) of 96{\%}. Among those using a second-generation antipsychotic with an indication for treatment-resistant depression, the sensitivity, specificity, and PPV of Medicaid claims for identifying off-label use were 41{\%}, 86{\%}, and 87{\%}, respectively. Conclusions: Medicaid claims data had high predictive ability for identifying users of second-generation antipsychotics who did not have documentation of schizophrenia or bipolar disorder in the medical record. The predictive utility of the claims was diminished when the analyses were limited to patients using a second-generation antipsychotic with an indication for treatment-resistant depression.",
author = "Hartung, {Daniel M.} and Luke Middleton and Bentson McFarland and Haxby, {Dean G.} and Marian McDonagh and McConnell, {Kenneth (John)}",
year = "2013",
month = "12",
day = "1",
doi = "10.1176/appi.ps.005482012",
language = "English (US)",
volume = "64",
pages = "1236--1242",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "12",

}

TY - JOUR

T1 - Use of administrative data to identify off-label use of second-generation antipsychotics in a medicaid population

AU - Hartung, Daniel M.

AU - Middleton, Luke

AU - McFarland, Bentson

AU - Haxby, Dean G.

AU - McDonagh, Marian

AU - McConnell, Kenneth (John)

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Objective: The use of second-generation antipsychotics for conditions not approved by the U.S. Food and Drug Administration (FDA) is a prevalent phenomenon with important implications. The objective of this study was to determine the accuracy of administrative claims for identifying off-label use of second-generation antipsychotics in a Medicaid population in 2009. Methods: The authors estimated the sensitivity, specificity, positive predictive values (PPV), and negative predictive values of Medicaid claims data for detecting off-label use of second-generation antipsychotics in the electronic health records of 788 patients. Separate estimates were calculated for patients without schizophrenia and bipolar disorder, the two most long-standing FDA indications for use of second-generation antipsychotics, and for a subset of patients using a second-generation antipsychotic with indications for treatment-resistant depression. Results: Medicaid claims determined a lack of schizophrenia and bipolar disorder in the medical record with a sensitivity of 72% and a specificity of 85%. The prevalence of identifying neither diagnosis was 83%, which was associated with a predictive ability (PPV) of 96%. Among those using a second-generation antipsychotic with an indication for treatment-resistant depression, the sensitivity, specificity, and PPV of Medicaid claims for identifying off-label use were 41%, 86%, and 87%, respectively. Conclusions: Medicaid claims data had high predictive ability for identifying users of second-generation antipsychotics who did not have documentation of schizophrenia or bipolar disorder in the medical record. The predictive utility of the claims was diminished when the analyses were limited to patients using a second-generation antipsychotic with an indication for treatment-resistant depression.

AB - Objective: The use of second-generation antipsychotics for conditions not approved by the U.S. Food and Drug Administration (FDA) is a prevalent phenomenon with important implications. The objective of this study was to determine the accuracy of administrative claims for identifying off-label use of second-generation antipsychotics in a Medicaid population in 2009. Methods: The authors estimated the sensitivity, specificity, positive predictive values (PPV), and negative predictive values of Medicaid claims data for detecting off-label use of second-generation antipsychotics in the electronic health records of 788 patients. Separate estimates were calculated for patients without schizophrenia and bipolar disorder, the two most long-standing FDA indications for use of second-generation antipsychotics, and for a subset of patients using a second-generation antipsychotic with indications for treatment-resistant depression. Results: Medicaid claims determined a lack of schizophrenia and bipolar disorder in the medical record with a sensitivity of 72% and a specificity of 85%. The prevalence of identifying neither diagnosis was 83%, which was associated with a predictive ability (PPV) of 96%. Among those using a second-generation antipsychotic with an indication for treatment-resistant depression, the sensitivity, specificity, and PPV of Medicaid claims for identifying off-label use were 41%, 86%, and 87%, respectively. Conclusions: Medicaid claims data had high predictive ability for identifying users of second-generation antipsychotics who did not have documentation of schizophrenia or bipolar disorder in the medical record. The predictive utility of the claims was diminished when the analyses were limited to patients using a second-generation antipsychotic with an indication for treatment-resistant depression.

UR - http://www.scopus.com/inward/record.url?scp=84888864525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888864525&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.005482012

DO - 10.1176/appi.ps.005482012

M3 - Article

C2 - 23999754

AN - SCOPUS:84888864525

VL - 64

SP - 1236

EP - 1242

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 12

ER -